Calcitonin and phosphorus association for osteoporosis treatment - pref. also contg. magnesium

摘要

Compsns. for the treatment of osteoporosis contain an association of calcination and phosphorus (e.g. inorganic phosphate such as sodium or mono-magnesium phosphate or glycine phosphate) and pref also contain magnesium. Pref. compsns. contain 1500-3000 Medical Research Council (MRC) units of calcitonin associated with 180-360 g of phosphorus (as element) and 18-36 g of magnesium. The effects of calcitonin and phosphorus cpds. on bone formation has been studied, the present invention shows that together they exert a synergistic effect. Admin. of calcitonin in short treatments (sequential treatment) diminishes osteoclastic activity and the duration of the inversion phase, stimulates osteoblastic activity and avoids the troubles of prolonged treatment (reduction of formation of Basic Multicellular Units (BMU)). Pref. 30-70 MRC units per day are injected for 5 days in each 3 week period, whilst 1-2 g of phosphorus (as element) and opt. 0.1-0.2 g of magnesium (as element) are administered each day (continuously), The phosphorus and opt. magnesium are usually administered orally. A usual treatment course is for a period of 4-8 months.